Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Our Experts

Ulka Vaishampayan, MD

Ulka Vanshampayian
  • Professor, Internal Medicine Division of Hematology/ Oncology University of Michigan
  • Chair, Phase I Therapeutics, Rogel Cancer Center
  • Co-Leader TACR Program, Rogel Cancer Center

Ulka Vaishampayan, MD, is a Professor of Internal Medicine, Leader of the Translational and Clinical Research Program, and the Director of the Phase 1 Program at the University of Michigan Rogel Cancer Center. In 2022 she was endowed with Beverly S. Mitchell, M.D. Research Professorship in Cancer Research. She serves as the Chair of the SWOG Advanced Renal Committee, a member of the National Cancer Institute (NCI) Renal Task Force, and a board member of the Michigan Society of Hematology/Oncology.

Dr. Vaishampayan specializes in the treatment of genitourinary malignancies, including prostate cancer, bladder cancer, and renal cell carcinoma, and her research focuses on translational drug development. She is PI of the Department of Defense Kidney Cancer Consortium site and a recipient of the Prostate Cancer Foundation Challenge Award. She has completed leadership training and has acquired the prestigious Fellowship of the Advisory Board (FAB). She has 250+ publications in a number of peer-reviewed journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Clinical Cancer Research.